224Ra Radiopharmaceuticals with 212Pb Complexing Agents
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The use of 224Ra in radiopharmaceuticals is limited due to its short half-life and the production of undesirable daughter nuclides, such as 212Pb, which cause toxicity and require laborious purification, leading to a short shelf life and restricted use, while current methods for managing these daughter nuclides are impractical for clinical application.
Innovation Solution
A radiopharmaceutical solution comprising 224Ra and a complexing agent like EDTMP or TCMC-labeled monoclonal antibodies that specifically target and complex 212Pb, minimizing off-target effects and allowing for improved distribution and retention in bone tissues, thereby enhancing therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If 224Ra is used in radiopharmaceuticals, then therapeutic efficacy is improved due to alpha particle emission, but daughter nuclides such as 212Pb cause toxicity and require laborious purification
Solution Approach 1:
The patent extracts the harmful daughter nuclides (212Pb, 212Bi) from the 224Ra solution through purification processes before administration. This separation removes the toxic components while retaining the therapeutic 224Ra, directly resolving the contradiction between maintaining therapeutic efficacy and eliminating harmful effects.
Solution Approach 2:
The patent modifies the chemical parameters of the solution by adjusting pH, adding complexing agents, and controlling redox conditions to prevent the formation or reduce the toxicity of daughter nuclides. These parameter changes allow the system to maintain therapeutic benefits while minimizing harmful effects.
2Object-affected harmful factors
If purification methods are applied to remove daughter nuclides, then toxicity is reduced, but the process becomes laborious and shelf life is shortened
Solution Approach 1:
The patent performs purification steps immediately before administration rather than requiring complex ongoing purification systems. By preparing purified 224Ra solutions in advance with controlled daughter nuclide levels and stabilizing them with complexing agents, the system reduces toxicity without requiring complex purification equipment at the point of use.
Solution Approach 2:
The patent introduces complexing agents as intermediary substances that bind to daughter nuclides, preventing their harmful effects without requiring complete removal. These intermediaries simplify the purification process by chemically managing the daughter nuclides in a controlled manner rather than requiring their complete elimination.
3Object-affected harmful factors
If complexing agents are added to manage daughter nuclides, then off-target effects are minimized, but the solution complexity increases
Solution Approach 1:
The patent uses complexing agents as intermediary substances that selectively bind to daughter nuclides (212Pb, 212Bi) but not to the parent 224Ra. This selective binding minimizes off-target effects by directing daughter nuclides to specific locations or rendering them less toxic, while the simplicity of adding a chemical agent keeps the overall solution complexity manageable.
Solution Approach 2:
The patent applies complexing agents with specific chemical properties tailored to bind certain daughter nuclides while leaving the parent radionuclide unaffected. This local quality approach allows different components of the solution to have different functions - the complexing agent manages daughter nuclides locally without interfering with the overall therapeutic action of 224Ra.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution enables targeted therapy with reduced toxicity and extended shelf life of 224Ra solutions, allowing for effective treatment of skeletal metastases and addressing circulating tumor cells, with improved bone-to-soft tissue ratios and enhanced therapeutic potential.
Implementation Method 1
the complexing agent EDTMP which complexes with 212Pb and specifically targets it to the bone
Implementation Method 2
Alpha-emitting radionuclides are highly cytotoxic and the alpha particles produced are of high linear energy, which is delivering a high amount of ionization over a short range, causing destruction of DNA
Implementation Method 3
delivering a high amount of ionization over a short range
Implementation Method 4
The solutions can be administered intravenously to patients
Data Source
AI summary
The present invention relates to radiopharmaceutical compositions comprising the mother nuclide 224Ra, its daughter nuclide 212Pb, and a complexing agent that complexes with the daughter nuclide. The use of targeted chelate scavengers for 224Ra daughter nuclide opens up the possibility for using 224Ra based solutions for medial treatments.